• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

作者信息

Ribbing Jakob, Hooker Andrew C, Jonsson E Niclas

机构信息

Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Uppsala University, P.O. Box 591, Uppsala 75124, Sweden.

出版信息

J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):117-37. doi: 10.1007/s10928-007-9079-8. Epub 2007 Nov 8.

DOI:10.1007/s10928-007-9079-8
PMID:17990085
Abstract

The ultimate goal in drug development is to establish the manner of safe and efficacious administration to patients. To achieve this in an efficient way the information contained in the clinical studies should contribute to the increasing pool of accumulated knowledge. The aim of this simulation study is to investigate different knowledge-propagation strategies when the data is analysed using a model-based approach in NONMEM. Pharmacokinetic studies were simulated according to several scenarios of the underlying model and study design, including a population-optimal design based on analysis of a previous study. Five approaches with different degrees of knowledge propagation were investigated: analysing the studies pooled into one dataset, merging the results from analysing the studies separately, fitting a pre-specified model that has been selected from a previous study on either the most recent study or on the pooled dataset, or naïvely analysing the most recent study without any regards to any previous study. The approaches were evaluated on what model was selected (qualitative knowledge, investigated by stepwise covariate selection within NONMEM) as well as parameter precision (quantitative knowledge) and predictive performance of the model. Pooling all studies into one dataset is the best approach for identifying the correct model and obtaining good predictive performance and merging the results of separate analyses may perform almost as well. Fitting a pre-specified model on new data is fast, without selection bias, and sanctioned for model-based confirmatory analyses. However, fitting the same pre-specified model to all available data is still fast and can be expected to perform better in terms of predictive performance than the unbiased alternative. Using ED-optimal design of sample times and stratification of subjects from different subgroups is a successful strategy which allows sparse sampling and handles prior parameter uncertainty.

摘要

相似文献

1
Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.
J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):117-37. doi: 10.1007/s10928-007-9079-8. Epub 2007 Nov 8.
2
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.
3
Semi-parametric Bayesian regression for subgroup analysis in clinical trials.用于临床试验亚组分析的半参数贝叶斯回归
J Biopharm Stat. 2019;29(6):1024-1042. doi: 10.1080/10543406.2019.1572613. Epub 2019 Feb 12.
4
Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.群体药代动力学协变量模型的效能、选择偏倚及预测性能
J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34. doi: 10.1023/b:jopa.0000034404.86036.72.
5
[Meta-analysis of the Italian studies on short-term effects of air pollution].[意大利关于空气污染短期影响研究的荟萃分析]
Epidemiol Prev. 2001 Mar-Apr;25(2 Suppl):1-71.
6
Bayesian analysis of hierarchical pattern-mixture models for clinical trials data with attrition and comparisons to commonly used ad-hoc and model-based approaches.针对存在失访情况的临床试验数据的分层模式混合模型的贝叶斯分析,以及与常用的临时方法和基于模型的方法的比较。
J Biopharm Stat. 2005;15(3):383-402. doi: 10.1081/BIP-200056511.
7
Model averaging for treatment effect estimation in subgroups.亚组中治疗效果估计的模型平均法。
Pharm Stat. 2017 Mar;16(2):133-142. doi: 10.1002/pst.1796. Epub 2016 Dec 9.
8
Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization.NONMEM 设计教程:临床试验评估与优化。
CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1452-1465. doi: 10.1002/psp4.12713. Epub 2021 Oct 19.
9
Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.第2部分。开发增强的统计方法,以评估与多种空气污染物的未知数量主要来源相关的健康影响。
Res Rep Health Eff Inst. 2015 Jun(183 Pt 1-2):51-113.
10
Bayesian robustness in meta-analysis for studies with zero responses.零反应研究的Meta分析中的贝叶斯稳健性
Pharm Stat. 2016 May;15(3):230-7. doi: 10.1002/pst.1741. Epub 2016 Feb 23.

引用本文的文献

1
Informative study designs to identify true parameter-covariate relationships.用于识别真实参数-协变量关系的信息性研究设计。
J Pharmacokinet Pharmacodyn. 2009 Apr;36(2):147-63. doi: 10.1007/s10928-009-9115-y. Epub 2009 Mar 27.

本文引用的文献

1
Drug interaction studies: study design, data analysis, and implications for dosing and labeling.药物相互作用研究:研究设计、数据分析以及对给药和标签的影响。
Clin Pharmacol Ther. 2007 Feb;81(2):298-304. doi: 10.1038/sj.clpt.6100054.
2
The application of a Bayesian approach to the analysis of a complex, mechanistically based model.贝叶斯方法在基于机制的复杂模型分析中的应用。
J Biopharm Stat. 2007;17(1):65-92. doi: 10.1080/10543400600851898.
3
Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?
基于人群的临床药物相互作用评估:定性指标还是定量测量?
J Clin Pharmacol. 2006 Nov;46(11):1268-89. doi: 10.1177/0091270006294278.
4
Model-based drug development: the road to quantitative pharmacology.基于模型的药物研发:通往定量药理学之路。
J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):369-93. doi: 10.1007/s10928-006-9010-8. Epub 2006 Jun 13.
5
Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein.
Clin Pharmacokinet. 2006;45(2):177-97. doi: 10.2165/00003088-200645020-00004.
6
Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.药物计量学对药物批准和标签决策的影响:对42份新药申请的调查
AAPS J. 2005 Oct 7;7(3):E503-12. doi: 10.1208/aapsj070351.
7
A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective.群体药代动力学分析结果报告指南:瑞典视角
AAPS J. 2005 Oct 5;7(2):45. doi: 10.1208/aapsj070245.
8
Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.囊性纤维化患者中伊曲康唑群体药代动力学的模型判别与参数估计的优化设计
J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):521-45. doi: 10.1007/s10928-005-0026-2.
9
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.PsN工具包——一组使用NONMEM进行非线性混合效应建模的计算机密集型统计方法。
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57. doi: 10.1016/j.cmpb.2005.04.005.
10
Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.群体药代动力学协变量模型的效能、选择偏倚及预测性能
J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34. doi: 10.1023/b:jopa.0000034404.86036.72.